CCM
TCRT icon

Chilton Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Chilton Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16
Closed -$52 – 671
2024
Q3 		$52 Buy
+16
New +$57 ﹤0.01% 639

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Chilton Capital Management's TCRT Position: Q4 2024 in Review

Chilton Capital Management sold out of Alaunos Therapeutics (TCRT) in Q4 2024, closing a stake of 16 shares — an estimated $52 sold.

Chilton Capital Management first reported a position in TCRT in Q3 2024 and held it in 1 quarter. The position peaked at $52 in Q3 2024. 30 funds tracked by Wall St. Rank hold TCRT as of Q4 2024.

  • Chilton Capital Management reported no remaining Alaunos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Chilton Capital Management sold 16 Alaunos Therapeutics shares in Q4 2024, an estimated $52.
  • Chilton Capital Management first reported a position in Alaunos Therapeutics in Q3 2024 and held it in 1 quarter.
  • Chilton Capital Management's Alaunos Therapeutics position peaked at $52 in Q3 2024.
  • 30 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2024.

Based on Chilton Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.